Background Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. We assessed safety, tolerance, and efficacy of sirolimus in a prospective, biomarker-driven, open-label clinical trial.
Findings Between March 9, 2009, and Dec 8, 2014, 43 patients were enrolled, three of whom did not meet eligibility criteria. 11 of the 40 eligible patients discontinued study treatment because of intolerance (n=2) or non-compliance (n=9). SLEDAI and BILAG disease activity scores were reduced during 12 months of treatment in 16 (55%) of 29 patients who completed treatment. Mean SLEDAI score decreased from 10·2 (SD 5·6) at enrolment to 4·8 (4·5) after 12 months of treatment (p<0·001) and the mean total BILAG index score decreased from 28·4 (12·4) at enrolment to 17·4 (10·7) after 12 months of treatment (p<0·001). The mean daily dose of prednisone required to control disease activity decreased from 23·7 mg (SD 9·6) 
CD8
-double-negative T cells after 12 months. CD8 + memory T cells were selectively expanded in SRI-responders. Patient liver function and lymphocyte counts were unchanged. Although HDL-cholesterol (Z=-2·50, p=0·012), neutrophil counts (Z=-1·92, p=0·054), and haemoglobin (Z=-2·83, p=0·005) were moderately reduced during treatment, all changes occurred within a range that was considered safe. Platelet counts were slightly elevated during treatment (Z=2·06, p=0·0400).
Interpretation These data show that a progressive improvement in disease activity is associated with correction of proinflammatory T-cell lineage specification in patients with active systemic lupus erythematosus during 12 months of sirolimus treatment. Follow-up placebo-controlled clinical trials in diverse patient populations are warranted to further define the role of mTOR blockade in treatment of systemic lupus erythematosus.
Introduction
Systemic lupus erythematosus is a chronic inflam matory disease that primarily affects women of childbearing age, with debilitating and potentially life threatening consequences. 
Research in context
Evidence before this study An unmet need exists for treatment in systemic lupus erythematosus. Mammalian target of rapamycin (mTOR) activation has been identified as a driver of pro-inflammatory lineage skewing in the immune system. We searched PubMed for English language articles published between Jan 1, 2000, and Oct 13, 2017, using the search terms "sirolimus," "rapamycin," or "mTOR" and "lupus". We found that research investigating the blockade of mTOR by sirolimus has been limited to a single retrospective study and two confirmatory case reports, which suggest that sirolimus has clinical efficacy in patients with systemic lupus erythematosus.
Added value of this study
This is the first prospective study of sirolimus in patients with systemic lupus erythematosus. This open-label study shows that treatment with sirolimus is safe, with rapid and lasting improvement of disease activity after 12 months of treatment resulting from the blockade of pro-inflammatory T-cell lineage specification in patients with active systemic lupus erythematosus. The depletion of CD8 effector-memory T cells predicts therapeutic response, and the progressive restoration of this cell population occurs with clinical improvement.
Implications of all the available evidence
The results of this study show that sirolimus is potentially a safe and efficacious treatment in patients with active systemic lupus erythematosus who are unresponsive to, or intolerant of, conventional medications. The results warrant double-blind placebo-controlled follow-up studies with sirolimus alone or in combination with potentially synergistic interventions, such as acetylcysteine, in larger and more diverse patient populations.
See Online for appendix and the production of autoantibodies.
1 Activation of the mechanistic target of rapamycin (mTOR) has emerged as a key driver of abnormal lineage specification within the immune system, 4 which has been attributed to metabolic stress in people with systemic lupus erythematosus.
5-8 Although mTOR activation 9 and its therapeutic reversal were originally identified in the T cells of patients with systemic lupus erythematosus, 10 studies have also reported mTOR activation in parenchymal organs such as the liver in mice 11 and the kidneys in patients with antiphospholipid syndrome. 12 mTOR is a serinethreonine kinase that takes its name after rapamycin, an antifungal antibiotic pro duced by Streptomyces hygroscopicus, a soil bacterium from Easter Island, known by its inhabitants as Rapa Nui.
13 Rapamycin effectively inhibits antigeninduced Tcell proliferation, 14 and has been developed as a medication to prevent organ transplant rejection under the generic designation of sirolimus.
15 Sirolimus forms a highaffinity complex with its cellular receptor, FKBP12, a 12 kD protein that is overexpressed in lupus T cells. 9 This complex of sirolimus and FKBP12 blocks mTOR activation. 16 In vivo, sirolimus completely abrogated autoimmunity in lupusprone mice, 17, 18 and blocked disease activity in a retrospective study of patients with systemic lupus erythematosus. 10 We initiated this prospective study to assess tolerance, safety, and the metabolic, immuno logical, and therapeutic effect of sirolimus in patients with severe systemic lupus erythematosus who are intolerant of, or do not respond to, other conventional medications.
Methods

Study design and participants
We did a prospective, singlearm, openlabel, phase 1/2 trial at the Division of Rheumatology, State University of New York Upstate Medical University (Syracuse, NY, USA) with approval from the institutional review board and the US Food and Drug Administration (IND 101566). The study protocol is available online.
We assessed the safety and efficacy of sirolimus for patients with active systemic lupus erythematosus. We also obtained blood from a healthy control group matched with patients for age, sex, and ethnicity, and freshly isolated cells from healthy control participants were used in parallel as controls for immunological studies (appendix pp 3-9).
We enrolled patients aged 18 years or older with systemic lupus erythematosus that fulfilled four or more of 11 diagnostic criteria defined by the American College of Rheumatology. 19, 20 We anticipated that most patients enrolled in the study would have active disease (Systemic Lupus Erythematosus Disease Activity Index [SLEDAI] score ≥4) 21 and were receiving prednisone 10 mg or more per day, but these were not formal inclusion criteria. Patients with allergy or intolerance to sirolimus, and patients with lifethreatening manifest ations of systemic lupus erythematosus (eg, cerebritis substantiated by inflam matory MRI lesions, catastrophic antiphospholipid antibody syndrome, rapid progressive glomerulo nephritis requiring intravenous cyclophospha mide, or a glomerular filtration rate of <40 mL/min) were excluded. Patients with proteinuria exceeding 500 mg/24 h, a urine protein to creatinine ratio higher than 0·5, anaemia (haemo globin <10 g/dL), leucopenia (white blood cell [WBC] count <3000 cells per µL), or thrombocytopenia (platelet count <100 000 cells per µL) were excluded. Patients with a WBC count of 3000-3500 per µL, haemoglobin concentration of 10-12 g/dL, or platelet counts of 100 000-150 000 per µL were monitored every week for 1 month. If WBC and platelet counts were sustained or improved, patients were followed up according to standard protocol. Patients with total cholesterol concentrations of more than 300 mg/dL or triglyceride concentrations of more than 400 mg/dL were
